Medical imaging has evolved far beyond simply identifying fractures or locating tumors. Today, advanced imaging technologies are helping clinicians understand how diseases behave, predict treatment response, and personalize therapies for individual patients. This transformation has been driven by the emergence of radiographic and radiomic biomarkers, two rapidly growing areas in precision medicine.
These biomarkers provide valuable anatomical, functional, and molecular insights without the need for invasive procedures. From cancer care and neurology to cardiovascular medicine, imaging biomarkers are becoming essential tools for diagnosis, monitoring, and prognostic prediction.
As artificial intelligence and computational medicine continue to advance, medical images are no longer viewed as static pictures. Instead, they are increasingly treated as data-rich sources capable of revealing hidden disease patterns and biological behavior.1
Radiographic biomarkers are measurable indicators obtained through medical imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), ultrasound, and X-rays.2 These biomarkers reflect normal physiological processes, disease-related changes, or the body’s response to treatment.
Unlike traditional laboratory biomarkers that rely on blood or tissue samples, imaging biomarkers offer a non-invasive way to assess organs and tissues in real time. They can be qualitative, based on visual assessment, or quantitative, involving numerical measurements generated through imaging software.
Examples of commonly used radiographic biomarkers include:
Coronary artery calcium scoring
Tumor size measurements
PET standardized uptake value (SUV)
Tissue perfusion imaging
Molecular imaging markers such as PD-L1 expression
These imaging-derived biomarkers have significantly improved disease detection and treatment monitoring across multiple specialties.3
MRI-based biomarkers are among the most widely used imaging biomarkers because of their excellent soft tissue resolution and ability to provide detailed anatomical information without radiation exposure.
MRI scans are routinely used to diagnose:
Joint and musculoskeletal disorders
Brain abnormalities
Tumor progression
Cartilage degeneration
Vascular and perfusion-related changes
In oncology, MRI biomarkers help monitor tumor size, tissue vascularity, and response to chemotherapy or immunotherapy. Functional MRI techniques can also evaluate brain activity and connectivity patterns in neurological disorders.
In patients with neurodegenerative diseases such as Alzheimer's disease, MRI can identify structural brain changes long before severe clinical symptoms become apparent.
Computed tomography remains one of the most important imaging modalities in modern medicine. CT-based biomarkers are especially valuable for evaluating structural abnormalities and quantifying disease burden.
One of the best-known examples is coronary artery calcium scoring, which helps predict cardiovascular disease risk. CT imaging also plays a central role in lung cancer screening by identifying pulmonary nodules at an early stage.
Advanced CT analysis can provide detailed quantitative information regarding:
Tumor volume
Tissue density
Fibrosis
Emphysema
Vascular calcification
Because CT scans offer rapid imaging with high spatial resolution, they are frequently used in emergency medicine, oncology, and cardiovascular care.
PET imaging provides metabolic and molecular information that complements anatomical imaging modalities such as CT and MRI.
Unlike conventional scans that mainly show structure, PET imaging reveals how tissues function biologically. PET biomarkers are particularly useful in:
Cancer staging
Monitoring treatment response
Evaluating brain disorders
Assessing cardiac metabolism
One of the most commonly used PET biomarkers is the standardized uptake value (SUV), which measures metabolic activity within tissues. Higher SUV values often indicate aggressive tumor behavior.
PET imaging has also become increasingly important in diagnosing neurodegenerative disorders, where altered glucose metabolism may appear before structural changes become visible.
Radiographic biomarkers offer several advantages that make them highly valuable in clinical practice.
Unlike tissue biopsies, imaging biomarkers allow repeated evaluation of disease progression without invasive procedures. This improves patient comfort and reduces procedural risks.
Imaging biomarkers enable clinicians to assess how a patient responds to treatment over time. This is particularly useful in oncology, where early treatment response can guide therapeutic decisions.
Traditional biopsies sample only a small tissue region, whereas imaging biomarkers can evaluate entire organs and even whole-body disease burden.
Many imaging biomarkers can identify abnormalities before symptoms become clinically obvious, allowing earlier intervention and potentially better outcomes.
Radiomic biomarkers represent an advanced form of imaging analysis that extracts large amounts of quantitative information from medical images using computational algorithms.4
Radiomics converts standard medical images into mineable data by analyzing features such as:
Tumor shape
Texture
Spatial distribution
Tissue heterogeneity
Edge sharpness
Many of these subtle imaging patterns cannot be detected through routine visual interpretation alone.
Radiomic analysis uses machine learning and artificial intelligence to identify imaging signatures associated with disease progression, treatment response, recurrence risk, and survival outcomes.1
Radiomic features can identify subtle changes in tissue architecture that may indicate early malignancy. This allows earlier diagnosis and improved treatment planning.
Radiomics can classify tumors according to imaging phenotype, helping clinicians identify patients who may respond differently to specific therapies.
This is especially important in modern oncology, where personalized medicine is becoming increasingly central to patient care.
Changes in tumor texture and heterogeneity may indicate developing treatment resistance even before visible tumor growth occurs. This allows clinicians to modify therapy earlier.
Radiomic biomarkers can help predict:
Overall survival
Disease-free survival
Risk of recurrence
Metastatic potential
These predictive models may improve risk stratification and long-term patient management.
One of the most promising advances in precision medicine is the merging of radiomics with molecular biology, an emerging field called radiogenomics. This approach combines imaging data with molecular and genetic information to give clinicians a deeper understanding of how diseases develop and behave.4
Molecular biomarkers provide insights into the genetic and biochemical pathways driving disease, while radiomic biomarkers capture the visible phenotypic effects of these molecular changes.
Studies suggest that combining molecular and radiomic biomarkers may improve:
Prognostic accuracy
Treatment selection
Prediction of therapeutic response
Understanding of tumor biology
For example, tumors expressing molecular markers such as PD-L1 may demonstrate distinct imaging characteristics on CT or PET scans.1
Despite their enormous potential, several barriers continue to limit the widespread clinical implementation of radiomics.
These include:
Lack of standardized imaging protocols
Variability in image acquisition techniques
Limited reproducibility across institutions
Dependence on high-quality imaging data
Need for large validation studies
Complex computational infrastructure
Radiomic analysis is highly sensitive to image quality and segmentation methods, making standardization essential for reliable clinical use.
Artificial intelligence is expected to play a major role in the future of imaging biomarkers.2 AI-driven systems can rapidly analyze large imaging datasets and identify disease patterns that may not be visible to human observers.
Future developments may include:
Automated radiomic analysis
AI-assisted cancer prediction models
Integration of imaging with genomic data
Personalized treatment algorithms
Earlier disease screening tools
As computational medicine advances, imaging biomarkers are likely to become central components of precision healthcare.
Radiographic and radiomic biomarkers are reshaping the future of medicine by transforming medical images into powerful diagnostic and predictive tools. Conventional imaging biomarkers provide valuable anatomical and functional information, while radiomics offers deeper insights into disease biology through advanced computational analysis.
With continued progress in artificial intelligence, molecular imaging, and machine learning, these biomarkers are expected to improve early disease detection, personalize treatment strategies, and enhance patient outcomes across multiple medical specialties.
Medical imaging is no longer limited to diagnosis alone, it is rapidly becoming a cornerstone of predictive and precision medicine.
1. Börner, Katy, Sarah A. Teichmann, Evan M. Quardokus, et al. “Anatomical Structures, Cell Types and Biomarkers of the Human Reference Atlas.” Nature Cell Biology 23 (2021): 1117–1128.
2. Subramanian, M., et al. “Types of Biomarkers and Their Applications.” Abcam Knowledge Center. Accessed May 19, 2026.
3. Boppana, Anusha, Seunghee Lee, Rajat Malhotra, Marc Halushka, Kyle S. Gustilo, Evan M. Quardokus, Bruce W. Herr II, Katy Börner, and Griffin M. Weber. “Anatomical Structures, Cell Types, and Biomarkers of the Healthy Human Blood Vasculature.” Scientific Data 10, no. 1 (2023): 452.
4. Ahmad, Anas, Mohammad Imran, and Haseeb Ahsan. 2023. "Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases" Pharmaceutics 15, no. 6: 1630.
